Related Experiment Videos
Structural and affinity studies of IgM polyreactive natural autoantibodies
1Immunohematology and Immunopathology Unit, Pasteur Institute, Paris, France.
Journal of Immunology (Baltimore, Md. : 1950)
|January 15, 1997
Summary
Natural polyreactive autoantibodies (NAA) bind diverse antigens with high affinity, similar to immune antibodies. Their structural analysis reveals restricted gene usage and germline configurations, challenging previous assumptions about polyreactivity.
Area of Science:
- Immunology
- Molecular Biology
- Structural Biology
Background:
- Natural polyreactive autoantibodies (NAA) are part of the normal B cell repertoire.
- NAA are known for binding multiple, dissimilar antigens.
- Previous assumptions suggested NAA bind antigens with low affinity and are encoded by germline genes.
Purpose of the Study:
- To investigate the binding avidities and structural characteristics of murine monoclonal NAA.
- To compare the binding kinetics and gene usage of NAA with immune antibodies.
- To explore the structural basis of polyreactivity in NAA.
Main Methods:
- Surface Plasmon Resonance (SPR) for determining binding avidities.
- Structural analysis of five murine monoclonal NAA.
- Amino acid sequencing and molecular modeling of antibody variable domains.
Main Results:
- All five NAA bound diverse antigens with kinetic constants comparable to immune antibodies.
- NAA expressed a restricted set of V(H), V(L), and D gene segments, with some shared genes.
- Antibody structures showed typical germline configurations and paratope side chain distributions similar to immune antibodies.
- No distinctive particularity in the CDR3 region length or charge was observed in NAA compared to immune antibodies.
Conclusions:
- NAA bind antigens with high affinity, similar to immune antibodies.
- Restricted V gene usage and germline configuration contribute to NAA characteristics.
- The structural features of NAA paratopes resemble those of immune antibodies, challenging the role of CDR3 in polyreactivity.